Cellebrite's 2026 Industry Trends Report Reveals Smartphones as the Leading Source of Digital Evidence in Investigations at 97%

97% cite smartphones as top evidence source, up 24 points from 2024 95% agree digital evidence increases solvability, yet 94% say complexity strains caseloads 65% believe AI can accelerate investigations, but one-third say policies prevent its use Cloud receptiveness hit 42%, yet two-thirds still rely on physical media TYSONS CORNER, Va. and PETAH TIKVA, Israel, Feb. 5, 2026 /PRNewswire/ -- Cellebrite (NASDAQ: CLBT), a global leader in AI-powered Digital Investigative and Intelligence solutions for the public and private sectors, today unveiled its 2026 Industry Trends Report, which surveyed 1,200 practitioners across 63 countries, marking the company's seventh annual report on how organizations collect, manage and analyze digital evidence.

PRNewsWire • Feb 5, 2026

Artisan Small Cap Fund Q4 2025 Portfolio Activity

During the quarter, we initiated new positions in nLIGHT, Guardant Health and Cellebrite. We also added to Bruker, Hexcel and Penumbra during the quarter. Along with Insmed, we also ended our investment campaigns in Integer Holdings and SharkNinja during the quarter.

Seeking Alpha • Jan 23, 2026

Cellebrite to Report Fourth-Quarter and Fiscal Year 2025 Financial Results on February 11, 2026

TYSONS CORNER, Va. and PETAH TIKVA, Israel, Jan. 21, 2026 /PRNewswire/ -- Cellebrite (NASDAQ: CLBT), a global leader in premier Digital Investigative solutions for the public and private sectors, today announced it will report its fourth-quarter and fiscal year 2025 financial results before the U.S. markets open on Wednesday, February 11, 2026.

PRNewsWire • Jan 21, 2026

Norwood Investment Partners Opens New $4.3 Million Cellebrite Position

Norwood initiated Cellebrite position and now holds 230,671 shares, worth an estimated $4.27 million. The stake represents 3.68% of 13F reportable assets under management.

The Motley Fool • Dec 9, 2025

Cellebrite: Solid Setup Going Into Next Year

Cellebrite remains a "Buy" as federal demand rebounds and platform adoption accelerates, supporting a strong long-term growth outlook. The federal segment returned to year-over-year growth in Q3, removing the primary bear case and confirming demand was delayed, not lost. Inseyets migration and rapid cloud/SaaS ARR growth—Guardian cloud ARR up >100% for five quarters—position CLBT for outsized ARR acceleration into 2026.

Seeking Alpha • Dec 5, 2025

10 AI Stocks Worth Buying Right Now

Artificial intelligence (AI) will reshape industries for decades, making early positioning in focused AI players critical. Smaller AI companies often offer more upside than megacaps that have already priced in the boom.

The Motley Fool • Dec 4, 2025

Cellebrite Completes Acquisition of Corellium, Extending the Industry's Most Advanced AI-Powered Digital Investigation Platform

TYSONS CORNER, Va. and PETAH TIKVA, Israel, Dec. 02, 2025 (GLOBE NEWSWIRE) -- Cellebrite (NASDAQ: CLBT), a global leader in AI-powered Digital Investigative and Intelligence solutions for the public and private sectors, today announced it has substantially expanded its capabilities through the acquisition of Corellium, a leader in Arm-based virtualization software.

GlobeNewsWire • Dec 2, 2025

Cellebrite DI Ltd. (CLBT) Presents at UBS Global Technology and AI Conference 2025 Transcript

Cellebrite DI Ltd. (CLBT) Presents at UBS Global Technology and AI Conference 2025 Transcript

Seeking Alpha • Dec 3, 2025

Cellebrite DI: Strong Q3, But Valuation And Technical Issues Could Weigh On The Stock (Rating Downgrade)

Cellebrite DI remains a long-term growth story, despite recent volatility and a modest stock decline since November 2024. CLBT's Q3 2025 earnings beat analyst expectations, with revenue up 18% year-over-year to $126 million and EPS of $0.14. Valuation and technical concerns persist, which could lead to further selling or an underperformance for the stock.

Seeking Alpha • Nov 22, 2025

Should Investors Buy Shares of Cellebrite Alongside Portolan Capital as They Double Down on the Stock?

Portolan Capital increased its Cellebrite position by 1,407,818 shares, worth an estimated $28.65 million. The transaction equates to approximately 1.20% of 13F reportable assets under management (AUM).

The Motley Fool • Nov 19, 2025